middl
east
respiratori
syndrom
mer
coronaviru
merscov
lineag
c
betacoronaviru
report
caus
sever
respiratori
tract
infect
date
laboratoryconfirm
case
infect
merscov
includ
merscov
associ
death
report
world
health
organ
countri
current
effect
therapeut
vaccin
avail
treat
prevent
merscov
infect
spike
protein
merscov
play
import
role
viru
attach
fusion
entri
target
cell
similar
coronavirus
protein
merscov
consist
subunit
subunit
respons
bind
virion
receptor
bind
domain
rbd
cellular
receptor
dipeptidyl
subunit
mediat
fusion
viral
cellular
membran
interact
domain
entri
viral
genet
materi
host
cell
thu
rbd
subunit
domain
subunit
serv
import
target
develop
antivir
agent
merscov
infect
recent
identifi
peptid
deriv
domain
merscov
protein
subunit
design
could
interact
domain
protein
subunit
form
sixhelix
bundl
complex
block
viral
fusion
replic
rang
replac
amino
acid
residu
posit
neg
charg
amino
acid
eg
e
posit
charg
amino
acid
eg
k
introduct
intramolecular
saltbridg
result
peptid
exhibit
improv
solubl
stabil
antimerscov
activ
howev
potenc
still
strong
enough
warrant
clinic
develop
screen
extralarg
phagedisplay
antibodi
fab
librari
ying
et
al
identifi
human
neutral
monoclon
antibodi
hmab
specif
rbd
protein
subunit
exhibit
highli
potent
neutral
activ
merscov
infect
vitro
vivo
xray
crystallographi
shown
bind
epitop
merscov
protein
almost
complet
overlap
bind
site
howev
futur
clinic
applic
could
limit
inabl
neutral
merscov
strain
mutat
rbd
like
mous
neutral
mab
similar
weak
studi
compar
sensit
pseudotyp
merscov
wildtyp
strain
strain
key
mutat
includ
detect
rbd
merscov
strain
isol
differ
region
differ
time
throughout
cours
mer
outbreak
found
strain
mutat
rbd
significantli
less
sensit
wildtyp
strain
neutral
activ
pseudovirus
without
mutat
show
equal
sensit
fusion
inhibitori
activ
interestingli
combin
strong
synerg
emerg
merscov
smediat
fusion
infect
pseudotyp
merscov
strain
without
mutat
rbd
suggest
combin
therapi
could
develop
clinic
use
treat
patient
infect
merscov
strain
without
mutat
rbd
cell
line
obtain
atcc
manassa
va
usa
cell
line
cell
bank
chines
academi
scienc
shanghai
china
two
cell
line
propag
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
peptid
synthes
solid
phase
peptid
synthesi
syn
inc
shanghai
china
human
mab
provid
prof
tianlei
ying
fudan
univers
shanghai
china
recombin
plasmid
encod
merscov
protein
mutat
kindli
provid
dr
lani
du
new
york
blood
center
ny
usa
merscov
pseudovirus
construct
describ
previous
briefli
cell
plate
tissu
cultur
flask
incub
h
cell
cotransfect
plasmid
encod
envdefect
luciferaseexpress
encod
protein
without
mutat
rbd
mass
ratio
use
vigofect
vigor
biotechnolog
beij
china
accord
manufactur
recommend
supernat
replac
fresh
dmem
h
posttransfect
harvest
incub
addit
h
order
remov
cell
debri
supernat
centrifug
rpm
min
follow
filtrat
filter
merscov
pseudoviru
supernat
quantifi
test
content
product
merscov
pseudoviru
merscov
pseudoviru
inhibit
assay
perform
previous
describ
briefli
cell
seed
cellswel
plate
incub
overnight
merscov
pseudoviru
incub
serial
dilut
inhibitor
min
follow
addit
cell
cell
incub
without
pseudoviru
viru
control
cell
control
respect
cultur
replac
fresh
medium
h
postinfect
incub
addit
h
cell
lyse
use
lysi
reagent
promega
madison
wi
usa
cell
lysat
transfer
costar
flatbottom
luminomet
plate
corn
costar
new
york
ny
usa
follow
addit
luciferas
substrat
promega
measur
luminesc
use
infinit
pro
tecan
austria
merscov
proteinmedi
fusion
perform
previous
describ
briefli
plasmid
paaviresmersegfp
encod
merscov
protein
transfect
cell
use
transfect
reagent
vigofect
vigor
biotechnolog
beij
china
target
cell
express
incub
cellswel
well
plate
h
effector
cell
express
merscov
protein
egfp
control
cell
express
egfp
preincub
cellswel
inhibitor
indic
concentr
phosphat
buffer
salin
pb
control
min
mixtur
cell
inhibitor
pb
ad
cell
well
follow
cocultur
h
cell
fuse
unfus
cell
fix
pfa
count
invert
fluoresc
microscop
nikon
tokyo
japan
fuse
cell
show
much
larger
size
weaker
fluoresc
intens
unfus
cell
diffus
egfp
one
cell
cell
figur
almost
fuse
cell
could
observ
group
neg
control
peptid
treatment
figur
concentr
inhibit
calcul
use
calcusyn
softwar
kindli
provid
dr
tc
chou
anim
experi
perform
ethic
guidelin
care
use
laboratori
anim
fudan
univers
protocol
approv
institut
laboratori
anim
care
use
committe
fudan
univers
approv
number
septemb
sixweekold
femal
specificpathogenfre
spf
balbc
mice
bodyweight
g
divid
group
mice
mice
group
intraperiton
ip
inject
mg
pb
alon
mg
pb
alon
combin
mg
pb
mg
pb
respect
mice
sedat
nembut
mgkg
bodi
weight
h
inject
inhibitor
respect
bled
retroorbit
blood
centrifug
rpm
min
stand
room
temperatur
h
sera
collect
heatinactiv
min
inhibitori
activ
inhibitor
merscov
pseudoviru
evalu
serum
describ
assess
potenti
synergist
effect
mix
indic
molar
concentr
ratio
alon
alon
includ
control
mixtur
serial
dilut
test
inhibitori
activ
merscov
pseudoviru
infect
describ
sampl
test
triplic
data
analyz
synergist
effect
calcul
combin
index
ci
use
calcusyn
program
ci
valu
indic
synergi
antagon
respect
synergi
divid
differ
strength
accord
ci
valu
follow
indic
strong
synerg
indic
strong
synerg
indic
synerg
indic
moder
synerg
indic
slight
synerg
fold
potenc
enhanc
calcul
ratio
concentr
inhibitor
test
alon
combin
determin
signific
differ
sensit
wildtyp
mutant
virus
inhibitor
inhibitori
activ
detect
sera
balbc
mice
treat
inhibitor
alon
combin
statist
analys
perform
use
twotail
unpair
student
ttest
use
graphpad
prism
version
valu
p
p
consid
statist
signific
signific
respect
first
investig
potenti
cooper
effect
combin
merscov
pseudoviru
infect
preliminari
studi
found
valu
inhibit
merscov
pseudoviru
infect
nm
nm
respect
therefor
test
inhibitori
activ
alon
alon
combin
molar
concentr
ratio
respect
shown
figur
tabl
combin
result
strong
synergist
inhibitori
activ
merscov
pseudoviru
infect
ci
valu
inhibit
includ
potenc
enhanc
result
suggest
merscov
fusion
inhibitori
peptid
merscov
neutral
mab
could
use
combin
enhanc
antimerscov
activ
next
test
potenti
synergist
activ
combin
merscov
proteinmedi
fusion
adjust
molar
concentr
ratio
combin
sinc
valu
inhibit
merscov
proteinmedi
fusion
preliminari
studi
nm
nm
respect
shown
figur
tabl
combin
also
exhibit
strong
synerg
merscov
proteinmedi
fusion
ci
enhanc
result
confirm
combin
merscov
fusion
inhibitor
human
neutral
mab
result
strong
synerg
proteinmedi
membran
fusion
target
differ
stage
merscov
fusion
entri
process
du
et
al
previous
shown
merscov
pseudovirus
mutat
rbd
detect
merscov
strain
isol
differ
region
differ
time
resist
neutral
activ
rbdspecif
mous
mab
present
studi
sensit
pseudotyp
merscov
strain
key
mutat
rbd
identifi
merscov
mutant
isol
outbreak
includ
along
wildtyp
merscov
compar
inhibitori
activ
peptid
alon
neutral
mab
alon
shown
tabl
resist
merscov
mutant
neutral
activ
wherea
pseudovirus
without
mutat
equal
sensit
fusion
inhibitori
activ
result
suggest
use
mab
alon
unabl
control
infect
merscov
strain
mutat
rbd
determin
whether
combin
also
exhibit
synergist
antivir
activ
infect
merscov
strain
mutat
rbd
domain
construct
pseudovirus
bear
merscov
protein
mutat
rbd
includ
domain
includ
test
sensit
inhibit
alon
alon
combin
shown
tabl
combin
exhibit
strong
synerg
infect
pseudotyp
merscov
strain
without
mutat
rbd
domain
ci
valu
less
potenc
enhanc
rang
suggest
combin
therapi
potenti
develop
treatment
patient
infect
differ
merscov
strain
includ
resist
rbdspecif
neutral
antibodi
determin
whether
combin
could
sustain
efficaci
vivo
compar
alon
test
antimerscov
pseudoviru
activ
inhibitor
sera
mice
treat
ip
inject
combin
respect
shown
figur
inhibitori
activ
detect
sera
mice
treat
alon
significantli
higher
detect
sera
mice
inhibit
inhibitor
hand
antimerscov
activ
detect
sera
mice
treat
combin
significantli
potent
detect
sera
mice
administ
alon
result
confirm
combin
afford
synerg
merscov
infect
vitro
vivo
high
mortal
merscovinfect
patient
call
develop
highli
effect
antimerscov
therapeut
although
other
previous
identifi
merscov
fusion
inhibitori
peptid
target
merscov
protein
domain
highli
potent
human
neutral
mab
target
merscov
protein
rbd
develop
limit
low
potenc
case
low
efficaci
neutral
merscov
strain
rbd
mutat
case
combinatori
use
drug
differ
mechan
action
ie
cocktail
regimen
wide
appli
clinic
exampl
combinatori
use
hiv
revers
transcriptas
rt
inhibitor
proteas
inhibitor
known
highli
activ
antiretroviru
therapi
haart
shown
signific
synerg
inhibit
infect
reduc
advers
effect
delay
emerg
drug
resist
thu
extend
lifespan
million
hivaid
patient
moreov
previous
show
combin
attach
inhibitor
rt
inhibitor
combin
andor
gener
hiv
fusion
inhibitor
target
differ
site
domain
exhibit
synergist
complementari
effect
infect
broad
spectrum
strain
includ
resist
hiv
attach
inhibitor
fusion
inhibitor
rt
inhibitor
studi
compar
antimerscov
activ
alon
alon
combin
found
inhibitori
activ
combin
significantli
potent
either
one
administ
alon
merscov
proteinmedi
fusion
merscov
pseudoviru
infect
suggest
synergist
activ
base
dual
mechan
action
wherebi
target
subunit
domain
inhibit
fusion
target
subunit
rbd
inhibit
bind
viru
attach
well
known
drug
synerg
expect
drug
act
differ
mechan
action
mix
togeth
merscov
pseudovirus
mutat
rbd
resist
rbdspecif
mab
equal
sensit
peptid
notabl
howev
combin
exhibit
strong
synergist
antivir
activ
pseudotyp
merscov
strain
includ
mutat
rbd
protein
even
resist
rbdspecif
mous
mab
also
demonstr
sera
mice
treat
combin
reveal
signific
efficaci
inhibit
merscov
pseudoviru
infect
compar
alon
collect
result
suggest
combinatori
strategi
overcom
weak
peptid
mab
time
take
advantag
uniqu
mechan
action
provid
sum
much
effect
inhibitori
activ
merscov
infect
either
peptid
mab
use
alon
strong
synergi
combin
expect
reduc
dosag
individu
inhibitor
combin
therapi
result
decreas
cost
toxic
thu
make
final
product
afford
safer
therefor
combin
therapi
show
promis
clinic
develop
